BevacizumabRecent, repeatedEvidence- NCT07895355 · RemeGen Co., Ltd. · Phase 2 · live · comparator · “Telisotuzumab adizutecan plus Bevacizumab” · registered Oct 2026
- NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2026
- NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Bevacizumab injection” · registered Aug 2026
- NCT07775287 · Genmab · Phase 3 · live · comparator · “Bevacizumab” · registered Aug 2026
- NCT07750041 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “bevacizumab + FOLFOXIRI” · registered Aug 2026
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 3844 studies | 3340 studies | comparator 31 · background 46 |
FluorouracilRecent, repeatedEvidence- NCT07844187 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Fluorouracil” · registered Sep 2026
- NCT07814417 · Eli Lilly and Company · Phase 2 · live · background · “5-fluorouracil” · registered Sep 2026
- NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Fluorouracil” · registered Aug 2026
- NCT07775287 · Genmab · Phase 3 · live · background · “5-FU” · registered Aug 2026
- NCT07737600 · lepu biopharma co ltd · Phase 2 · live · background · “5-Fluorouracil / Leucovorin Calcium” · registered Jul 2026
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 1520 studies | 1522 studies | background 69 · comparator 14 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07844187 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Oxaliplatin” · registered Sep 2026
- NCT07814417 · Eli Lilly and Company · Phase 2 · live · background · “Oxaliplatin” · registered Sep 2026
- NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Aug 2026
- NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Oxaliplatin injection” · registered Aug 2026
- NCT07775287 · Genmab · Phase 3 · live · background · “Oxaliplatin” · registered Aug 2026
| Sanofi35% of its industry studies | 1418 studies | 1521 studies | background 44 · comparator 7 |
LeucovorinRecent, repeatedEvidence- NCT07844187 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Calcium folinate (leucovorin calcium)” · registered Sep 2026
- NCT07814417 · Eli Lilly and Company · Phase 2 · live · background · “Leucovorin/levofolinate calcium” · registered Sep 2026
- NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Leucovorin” · registered Aug 2026
- NCT07775287 · Genmab · Phase 3 · live · background · “Leucovorin (Calcium Folinate)” · registered Aug 2026
- NCT07737600 · lepu biopharma co ltd · Phase 2 · live · background · “5-Fluorouracil / Leucovorin Calcium” · registered Jul 2026
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 1418 studies | 1419 studies | background 60 · comparator 12 |
FOLFIRI RegimenRecent, repeatedEvidence- NCT07790510 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · live · background · “FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU)” · registered Aug 2026
- NCT07702032 · Genmab · Phase 3 · live · background · “FOLFIRI” · registered Jul 2026
- NCT07323576 · Hoffmann-La Roche · Phase 2 · background · “FOLFIRI” · registered Jan 2026
- NCT07391566 · Luye Pharma Group Ltd. · Phase 2 · live · background · “FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)” · registered Dec 2025
- NCT07221357 · Bristol-Myers Squibb · Phase 3 · live · background · “FOLFIRI” · registered Oct 2025
| — | 1313 studies | 89 studies | background 33 · comparator 3 |
CetuximabRecent, repeatedEvidence- NCT07939815 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Nov 2026
- NCT07775287 · Genmab · Phase 3 · live · comparator · “Cetuximab” · registered Aug 2026
- NCT07702032 · Genmab · Phase 3 · live · comparator · “Cetuximab” · registered Jul 2026
- NCT07659795 · Verastem, Inc. · Phase 2 · live · background · “cetuximab” · registered Jun 2026
- NCT07595276 · Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 3 · live · comparator · “Erbitux®” · registered May 2026
| Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004) | 1218 studies | 1118 studies | background 33 · comparator 17 |
trifluridine tipiracil drug combinationRecent, repeatedEvidence- NCT07913360 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Trifluridine and Tipiracil” · registered Oct 2026
- NCT07730489 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “TAS-102” · registered Jul 2026
- NCT07549412 · Merck KGaA, Darmstadt, Germany · Phase 3 · live · comparator · “Trifluridine/Tipiracil (FTD-TPI)” · registered Apr 2026
- NCT06607458 · Delcath Systems Inc. · Phase 2 · live · comparator · “Trifluridine-tipiracil plus Bevacizumab Alone” · registered Sep 2024
- NCT06039202 · Holy Stone Healthcare Co., Ltd · Phase 2 · background · “TAS-102” · registered Sep 2023
| Otsuka Holdings Co., Ltd.52% of its industry studies | 1010 studies | 77 studies | comparator 10 · background 4 |
FOLFIRI-Ziv-aflibercept RegimenRecent, repeatedEvidence- NCT07702032 · Genmab · Phase 3 · live · background · “FOLFIRI” · registered Jul 2026
- NCT07323576 · Hoffmann-La Roche · Phase 2 · background · “FOLFIRI” · registered Jan 2026
- NCT07391566 · Luye Pharma Group Ltd. · Phase 2 · live · background · “FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)” · registered Dec 2025
- NCT07221357 · Bristol-Myers Squibb · Phase 3 · live · background · “FOLFIRI” · registered Oct 2025
- NCT06936527 · Fosun Pharma · Phase 2 · live · comparator · “Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI” · registered Apr 2025
| — | 99 studies | 55 studies | background 27 · comparator 2 |
pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07255664 · CuraCell TX AB · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2025
- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06699836 · CytoDyn, Inc. · Phase 2 · live · background · “200 mg pembrolizumab” · registered Nov 2024
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 88 studies | 1112 studies | background 15 |
IrinotecanRecent, repeatedEvidence- NCT07775287 · Genmab · Phase 3 · live · background · “Irinotecan” · registered Aug 2026
- NCT07474727 · Multitude Therapeutics Inc. · Phase 2 · live · background · “Irinotecan” · registered Mar 2026
- NCT07134205 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Irinotecan” · registered Aug 2025
- NCT06750094 · Johnson & Johnson · Phase 3 · live · background · “Irinotecan” · registered Dec 2024
- NCT06662786 · Johnson & Johnson · Phase 3 · live · background · “Irinotecan Hydrochloride” · registered Oct 2024
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 812 studies | 1014 studies | background 53 · comparator 8 |
CapecitabineRecent, repeatedEvidence- NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Capecitabine” · registered Aug 2026
- NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Capecitabine tablets” · registered Aug 2026
- NCT07737600 · lepu biopharma co ltd · Phase 2 · live · background · “Capecitabine” · registered Jul 2026
- NCT07412613 · Akeso · Phase 3 · live · comparator · “Capecitabine” · registered Feb 2026
- NCT07025239 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jun 2025
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 810 studies | 1013 studies | background 22 · comparator 6 |
fruquintinibRecent, repeatedEvidence- NCT07913360 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Fruquintinib” · registered Oct 2026
- NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Fruquintinib Capsules” · registered Aug 2026
- NCT07730489 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Fruquintinib” · registered Jul 2026
- NCT07621159 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Fruquintinib” · registered May 2026
- NCT07235293 · Kahr Bio Australia Pty Ltd · Phase 2 · live · comparator · “Fruquintinib” · registered Nov 2025
| HUTCHMED85% of its industry studiesUS: Takeda (FDA 2023)EU: Takeda (EMA 2024) | 88 studies | 88 studies | comparator 4 · background 4 |
Folfox protocolRecent, repeatedEvidence- NCT07323576 · Hoffmann-La Roche · Phase 2 · background · “FOLFOX” · registered Jan 2026
- NCT07284849 · Incyte Corporation · Phase 3 · live · background · “FOLFOX” · registered Dec 2025
- NCT07221357 · Bristol-Myers Squibb · Phase 3 · live · background · “FOLFOX” · registered Oct 2025
- NCT06936527 · Fosun Pharma · Phase 2 · live · comparator · “Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI” · registered Apr 2025
- NCT06598007 · Crossignal Therapeutics, Inc. · Phase 2 · live · background · “FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)” · registered Sep 2024
| Hoffmann-La Roche20% of its industry studies | 77 studies | 55 studies | background 14 · comparator 2 |
regorafenibRecent, repeatedEvidence- NCT07730489 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Regorafenib” · registered Jul 2026
- NCT07134205 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Regorafenib” · registered Aug 2025
- NCT06089330 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Regorafenib (Stivarga)” · registered Oct 2023
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Regorafenib” · registered Aug 2023
- NCT05600309 · Merck & Co., Inc · Phase 3 · comparator · “regorafenib” · registered Oct 2022
| Bayer80% of its industry studiesUS: Bayer (FDA 2012)EU: Bayer (EMA 2013) | 78 studies | 56 studies | background 6 · comparator 10 |
Modified FOLFOX6 RegimenRecent, repeatedEvidence- NCT07790510 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · live · background · “mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU)” · registered Aug 2026
- NCT07702032 · Genmab · Phase 3 · live · background · “mFOLFOX6” · registered Jul 2026
- NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “mFOLFOX6 regimen” · registered May 2024
- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “mFOLFOX6” · registered Mar 2024
- NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “mFOLFOX-6” · registered May 2023
| — | 66 studies | 77 studies | background 15 · comparator 3 |
NivolumabRecent, repeatedEvidence- NCT07527858 · Gilead Sciences · Phase 2 · live · background · “Nivolumab” · registered Apr 2026
- NCT06948448 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “Opdivo®” · registered Apr 2025
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
- NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Nivolumab” · registered May 2023
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 55 studies | 66 studies | background 10 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)” · registered Feb 2026
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2022
- NCT04956640 · Eli Lilly and Company · Phase 2 · live · background · “Carboplatin” · registered Jul 2021
| Eli Lilly and Company16% of its industry studies | 44 studies | 89 studies | background 11 |
GemcitabineRecent, repeatedEvidence- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “gemcitabine” · registered May 2024
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Gemcitabine” · registered Jul 2022
- NCT05116891 · Cantargia AB · Phase 2 · background · “G/C” · registered Oct 2021
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 44 studies | 77 studies | background 12 |
CisplatinRecent, repeatedEvidence- NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)” · registered Feb 2026
- NCT06428409 · Merck & Co., Inc · Phase 2 · live · background · “Cisplatin” · registered May 2024
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Gemcitabine Combined With Cisplatin” · registered Jul 2022
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2022
- NCT05116891 · Cantargia AB · Phase 2 · background · “G/C” · registered Oct 2021
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 44 studies | 66 studies | background 10 |
atezolizumabRecent, repeatedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
- NCT05733611 · Replimune, Inc. · Phase 2 · background · “atezolizumab” · registered Feb 2023
- NCT05456165 · Gritstone bio, Inc. · Phase 2 · background · “Atezolizumab” · registered Jul 2022
- NCT05425940 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered Jun 2022
- NCT05141721 · Seattle Project Corporation · Phase 3 · live · background · “Atezolizumab” · registered Nov 2021
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 45 studies | 34 studies | background 6 |
IpilimumabRecent, repeatedEvidence- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
- NCT05456165 · Gritstone bio, Inc. · Phase 2 · background · “Ipilimumab” · registered Jul 2022
- NCT05141721 · Seattle Project Corporation · Phase 3 · live · background · “Ipilimumab” · registered Nov 2021
- NCT03126110 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Apr 2017
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 44 studies | 33 studies | background 5 |
PaclitaxelRecent, repeatedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
- NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “paclitaxel” · registered Mar 2023
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Paclitaxel” · registered Jul 2022
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Oct 2020
- NCT04083599 · Genmab · Phase 2 · live · background · “Paclitaxel” · registered Sep 2019
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 33 studies | 77 studies | background 10 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “nab-paclitaxel” · registered May 2024
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Abraxane” · registered Jul 2022
- NCT04083599 · Genmab · Phase 2 · live · background · “Nab paclitaxel” · registered Sep 2019
- NCT03678883 · Actuate Therapeutics Inc. · Phase 2 · live · background · “Nab paclitaxel.” · registered Sep 2018
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 33 studies | 55 studies | background 9 |
LevoleucovorinRecent, repeatedEvidence- NCT07676162 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab” · registered Jun 2026
- NCT06750094 · Johnson & Johnson · Phase 3 · live · background · “Leucovorin calcium/Levoleucovorin” · registered Dec 2024
- NCT06662786 · Johnson & Johnson · Phase 3 · live · background · “Leucovorin calcium/Levoleucovorin” · registered Oct 2024
- NCT05253651 · Pfizer · Phase 3 · live · background · “levoleucovorin” · registered Feb 2022
- NCT04456699 · Merck & Co., Inc · Phase 3 · comparator · “Leucovorin/ levoleucovorin” · registered Jul 2020
| Aurobindo Pharma100% of its industry studies | 34 studies | 34 studies | background 6 · comparator 3 |
tislelizumabRecent, repeatedEvidence- NCT07468071 · Novartis · Phase 2 · live · background · “tislelizumab” · registered Mar 2026
- NCT07244705 · Anbogen Therapeutics, Inc. · Phase 2 · live · background · “Tislelizumab” · registered Nov 2025
- NCT05651022 · Indaptus Therapeutics, Inc · Phase 2 · live · background · “Tislelizumab” · registered Nov 2022
- NCT04952753 · Novartis · Phase 2 · background · “Tislelizumab” · registered Jun 2021
- NCT04699188 · Novartis · Phase 2 · live · background · “tislelizumab” · registered Jan 2021
| BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023) | 33 studies | 34 studies | background 5 |
DocetaxelRecent, repeatedEvidence- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Docetaxel” · registered Mar 2024
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
- NCT05116891 · Cantargia AB · Phase 2 · background · “DTX” · registered Oct 2021
- NCT04256707 · Karyopharm Therapeutics Inc · Phase 2 · background · “Docetaxel” · registered Feb 2020
- NCT04165031 · Eli Lilly and Company · Phase 2 · comparator · “Docetaxel” · registered Nov 2019
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 44 studies | background 6 · comparator 1 |
PemetrexedRecent, repeatedEvidence- NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)” · registered Feb 2026
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT04083599 · Genmab · Phase 2 · live · background · “Pemetrexed” · registered Sep 2019
- NCT03267316 · Cantargia AB · Phase 2 · background · “Pemetrexed” · registered Aug 2017
- NCT03085914 · Incyte Corporation · Phase 2 · background · “Pemetrexed” · registered Feb 2017
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 22 studies | 33 studies | background 6 |
TrastuzumabRecent, repeatedEvidence- NCT06589830 · Teligene US · Phase 2 · live · background · “Trastuzumab” · registered Sep 2024
- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Trastuzumab” · registered Mar 2024
- NCT05091528 · Silverback Therapeutics · Phase 2 · background · “trastuzumab” · registered Oct 2021
- NCT04579380 · Pfizer · Phase 2 · live · background · “trastuzumab” · registered Oct 2020
- NCT04464967 · NKGen Biotech, Inc. · Phase 2 · background · “Trastuzumab” · registered Jul 2020
| Hoffmann-La Roche55% of its industry studiesUS: Hoffmann-La Roche (FDA 1998) + 6 othersEU: Hoffmann-La Roche (EMA 2000) + 8 others | 22 studies | 34 studies | background 7 |
trastuzumab deruxtecanRecent, repeatedEvidence- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Trastuzumab deruxtecan” · registered Mar 2024
- NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “trastuzumab deruxtecan (T-DXd)” · registered Mar 2023
- NCT05091528 · Silverback Therapeutics · Phase 2 · background · “trastuzumab deruxtecan” · registered Oct 2021
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “T- Dxd” · registered Oct 2020
| Daiichi Sankyo53% of its industry studiesUS: Daiichi Sankyo (FDA 2019)EU: Daiichi Sankyo (EMA 2021) | 22 studies | 33 studies | background 4 |
PrednisoneRecent, repeatedPhase 4 trial recordedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Prednisone” · registered May 2026
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Prednisone/ prednisolone” · registered Jul 2022
| Johnson & Johnson11% of its industry studies | 22 studies | 22 studies | background 2 |
trametinibRecent, repeatedEvidence- NCT07468071 · Novartis · Phase 2 · live · background · “trametinib” · registered Mar 2026
- NCT05358249 · Novartis · Phase 2 · background · “trametinib” · registered Apr 2022
- NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
| GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014) | 23 studies | 22 studies | background 3 |
FluoropyrimidineRecent, repeatedEvidence- NCT05609370 · BeOne Medicines · Phase 2 · live · background · “Fluoropyrimidine (FP)” · registered Oct 2022
- NCT05141721 · Seattle Project Corporation · Phase 3 · live · background · “Fluoropyrimidine plus leucovorin” · registered Nov 2021
| Hoffmann-La Roche50% of its industry studies | 22 studies | 22 studies | background 2 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07222800 · Pfizer · Phase 3 · live · background · “Chemotherapy” · registered Oct 2025
- NCT05731947 · Syndax Pharmaceuticals · Phase 2 · comparator · “Chemotherapy” · registered Feb 2023
- NCT04868877 · Genmab · Phase 2 · background · “Chemotherapy” · registered Apr 2021
- NCT02327078 · Incyte Corporation · Phase 2 · background · “Chemotherapy” · registered Dec 2014
- NCT02202928 · Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 2 · background · “Chemotherapy” · registered Jul 2014
| — | 22 studies | 11 study | background 5 · comparator 2 |
CyclophosphamideRecent, repeatedEvidence- NCT07255664 · CuraCell TX AB · Phase 2 · live · background · “Cyclophosphamid” · registered Nov 2025
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
- NCT03563157 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered May 2018
- NCT03169777 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered May 2017
- NCT03085914 · Incyte Corporation · Phase 2 · background · “Cyclophosphamide” · registered Feb 2017
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 22 studies | 11 study | background 5 |